Monday, October 02, 2006
Sector Spotlight: Biotech
As for my other biotech position, DNA: Well, there is a lot to be happy about, if you owned this stock over the years. Moreover, with today's FDA approval of Rituxan and good data out of Avastin, I feel strongly about DNA's prospects going forward.
Biotech stocks are very risky investments. With my money, I don't have the medical background to really dig in my heals on a story, attempting to find the next MRK or DNA. It's simply too risky.
Instead, I buy leadership companies, with good pipelines and excellent track records-- typically big cap.
As for today's markets, I feel the ISM numbers coming in below consensus hurts. However, it wasn't weak enough to ring alarms or anything. Therefore, I do not believe the market will nose dive today, just trade moderately lower.
Finally, ahead of earnings season, keep a close eye on analyst downgrades. I seriously doubt those fuckers will head into 3rd quarter earnings with "Strong Buys" attached to every high multiple tech stock. Look for cowardice within the convictionless analyst community.
NOTE: Today, AAPL caught a downgrade and RACK got kicked in the groin by First albany-- reiterating underperform.
NOTE II: Please take the new "Fly Survey," on the left hand side of the page. Are you net long or short stocks?
The following biotech stock have mojo:
Generally, I try to avoid trades on earnings-- too risky.
However, considering the big moves in tech, it may be a good trade to sell short, prior to earnings.
Look for LRCX to set the tome, early.
As for oil: VLO should do well as the price of crude stabilizes. If crude starts to ramp, then so will VLO's profit margins.
Links to this post: